CN111939136A - Compound preparation containing ticagrelor and aspirin and preparation method thereof - Google Patents
Compound preparation containing ticagrelor and aspirin and preparation method thereof Download PDFInfo
- Publication number
- CN111939136A CN111939136A CN202010926574.7A CN202010926574A CN111939136A CN 111939136 A CN111939136 A CN 111939136A CN 202010926574 A CN202010926574 A CN 202010926574A CN 111939136 A CN111939136 A CN 111939136A
- Authority
- CN
- China
- Prior art keywords
- ticagrelor
- aspirin
- solid composition
- release
- quick
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
The invention belongs to the field of medical technical preparations, and relates to a compound preparation containing ticagrelor and aspirin and a preparation method thereof, which are suitable for being taken once a day. The invention discloses a compound preparation of ticagrelor and aspirin, which is a double-layer tablet and specifically comprises a quick-release core-spun layer and a slow-release layer. The preparation is taken once a day, so that the taking frequency is reduced, the risk of myocardial infarction and apoplexy is greatly reduced, and the compliance of patients in taking the preparation is improved. The combination of quick release and slow release of ticagrelor realizes quick and long-acting organic combination, and the combination of ticagrelor and aspirin enteric-coated tablets reduces the risk of bleeding, has small toxic and side effects, effectively reduces the platelet aggregation rate, and has better safety.
Description
Technical Field
The invention belongs to the field of pharmaceutical technology industry, and relates to a compound preparation containing ticagrelor and aspirin, which is suitable for being taken once a day.
Background
According to statistics, the disease with the highest death rate in the world at present is coronary heart disease, and accounts for 12.9% of the ten death disease ranks in the top. So far, the death rate of cardiovascular and cerebrovascular diseases in the United states accounts for 1/3-1/2 of the total death rate, wherein the death rate of coronary heart disease accounts for 50% -75% of the death rate of heart disease. Along with the change of domestic living environment and dietary habits of people, the incidence rate of cardiovascular and cerebrovascular diseases is also increased year by year. According to incomplete statistics, 38% of Chinese people die from cardiovascular diseases every year in China, wherein CHD accounts for 25% -50% of death population of cardiovascular diseases.
Coronary heart disease is the short term of coronary atherosclerotic heart disease, and is the myocardial damage change caused by myocardial ischemia and anoxia due to myocardial blood flow reduction caused by coronary atherosclerosis or other factors. The clinical manifestations of the drug are stable angina, unstable angina, arrhythmia, cardiogenic shock, etc. The disease is slow in onset, so that the medical history of most patients is long. The current clinical common treatment means include coronary heart disease medication, percutaneous coronary intervention, coronary artery bypass grafting and other main treatment means. But at present, the clinical treatment mainly comprises drug treatment.
At present, various medicines for treating coronary heart disease exist in clinic, wherein the antiplatelet medicine has an important effect in treating coronary heart disease, can effectively inhibit platelet aggregation in blood vessels, and prevent platelet aggregation and contraction, thereby achieving the aim of inhibiting thrombosis.
Currently, the drugs for resisting platelet aggregation on the market comprise aspirin, ticagrelor and clopidogrel hydrogen sulfate aspirin tablets. However, some doctors indicate that although clopidogrel hydrogen sulfide is a platelet aggregation inhibitor, the individual difference of the antiplatelet effect is large, and the treatment effect is influenced. The drug is used as a novel adenosine diphosphate P2Y12 receptor antagonist, the curative effect and the safety of the drug are both inhibited by platelets and verified and supported by the outcome of a patient, and PLATO research indicates that the curative effect of the drug is better than that of clopidogrel hydrogen sulfate, meanwhile, the resistance of clopidogrel hydrogen sulfate can be avoided, ADP and platelet receptors are selectively inhibited from being combined, and the activation of ADP mediated glycoprotein GP IIb/IIIa compound is inhibited, so that the platelet aggregation and the platelet aggregation not induced by ADP are inhibited.
Published data on the annual European cardiology show that 50% of patients with coronary heart disease are missed at least 1 time per month, and the more times the patients forget to take the medicine, the more risk of myocardial infarction and stroke will be greatly increased. In order to reduce this risk and improve patient compliance with medication, it is desirable to develop a once-a-day combination. Chinese patent document CN 106619549A discloses a ticagrelor and aspirin composite tablet and a preparation method thereof, wherein the compound oral preparation of the ticagrelor tablet and the aspirin tablet is taken 2 times a day, and the risk of missed administration is increased. At present, no compound oral preparation of ticagrelor sustained-release and aspirin enteric-coated tablets is on the market.
The invention discloses a compound preparation containing ticagrelor and aspirin, which is a double-layer tablet and specifically comprises a quick-release core-spun layer and a slow-release layer. The quick-release core-spun layer is formed by wrapping an aspirin enteric-coated tablet in the middle of a quick-release solid composition of ticagrelor and pressing, and the slow-release layer is formed by pressing a slow-release composition of ticagrelor. The preparation can be taken only once every day, so as to reduce risk of myocardial infarction and apoplexy, and improve compliance of patients. The combination of quick release and slow release of ticagrelor realizes quick and long-acting organic combination, and the combination of ticagrelor and aspirin enteric-coated tablets reduces the risk of bleeding, has small toxic and side effects and better safety.
Disclosure of Invention
The invention aims to provide a compound preparation containing ticagrelor and aspirin.
The invention provides a novel tabletting mode for a compound preparation of ticagrelor and aspirin, and the core-coated tablet and a double-layer tablet are organically combined. The ticagrelor sustained-release solid composition is firstly added into a die to be pre-pressed for forming, 1/2 of theoretical tablet weight of the ticagrelor immediate-release solid composition is then added into the die, an aspirin enteric-coated tablet is then placed in the middle of the die, and finally the ticagrelor immediate-release solid composition with the residual theoretical tablet weight of 1/2 is added into the die to be pressed into tablets.
The compound preparation of ticagrelor and aspirin is a double-layer tablet, and specifically comprises a quick-release core-spun layer and a slow-release layer. The combination of quick release and slow release of ticagrelor realizes quick and long-acting organic combination, and the combined use of ticagrelor and aspirin enteric-coated tablets can obviously improve the clinical symptoms of ACS patients, reduce the risk of bleeding, effectively reduce the platelet aggregation rate, and has small toxic and side effects and better safety.
The unit preparation of the compound preparation of ticagrelor and aspirin comprises 180mg of ticagrelor and 100mg of aspirin. The preparation is taken once a day, so that the taking frequency is reduced, the risk of myocardial infarction and apoplexy is greatly reduced, and the compliance of patients in taking the preparation is improved.
In order to achieve the aim, the ticagrelor and the aspirin are not directly contacted in a final solid preparation product mainly through separate granulation, mixing, coating, tabletting and other modes, so that the effect of releasing the drugs respectively and simultaneously is achieved.
A compound preparation of ticagrelor and aspirin is composed of a quick-release core-spun layer and a slow-release layer. The quick-release core-spun layer is formed by wrapping an aspirin enteric-coated tablet in the middle of a quick-release solid composition of ticagrelor and pressing, and the slow-release layer is formed by pressing a slow-release solid composition of ticagrelor.
The immediate release solid composition of the invention contains the following components: ticagrelor, lactose, anhydrous calcium hydrogen phosphate, polyvinylpyrrolidone, sodium carboxymethyl starch, red iron oxide and magnesium stearate.
The sustained-release solid composition of the present invention contains the components comprising: ticagrelor, lactose, anhydrous dibasic calcium phosphate, polyvinylpyrrolidone, hydroxypropylmethylcellulose, colloidal silicon dioxide, and magnesium stearate.
The aspirin enteric-coated tablet of the invention contains the following components: aspirin, microcrystalline cellulose, corn starch, methacrylic resin, talcum powder and triethyl citrate.
The compound preparation of ticagrelor and aspirin is prepared by mixing raw and auxiliary aspirin, tabletting and performing enteric coating by using a high-efficiency film coating machine. The quick-release solid composition and the slow-release solid composition of ticagrelor are respectively prepared into granules by using a wet mixing granulator, and the final granules are prepared by adding other corresponding additional auxiliary materials.
The compound preparation of ticagrelor and aspirin adopts round tablets when tablets are pressed.
The invention provides a novel tabletting mode for a compound preparation of ticagrelor and aspirin, and the core-coated tablet and a double-layer tablet are organically combined. Adding the ticagrelor sustained-release solid composition into a die for prepressing for forming, then adding 1/2 of the theoretical tablet weight of the ticagrelor quick-release solid composition into the die, then placing an aspirin enteric-coated tablet into the middle of the die, finally adding the ticagrelor quick-release solid composition with the rest theoretical tablet weight of 1/2 into the die for pressing into a tablet, and finally wrapping a layer of color layer outside the tablet to prepare the final compound preparation of ticagrelor and aspirin.
The compound preparation of ticagrelor and aspirin only needs to be taken once every day, so that the taking times are reduced, the risk of myocardial infarction and stroke is greatly reduced, and the compliance of patients in taking the medicine is improved. The combination of quick release and slow release of ticagrelor realizes quick and long-acting organic combination, reduces fluctuation of blood concentration, reduces bleeding risk by combining with aspirin enteric-coated tablets, and has small toxic and side effects and better safety.
Fig. 1.
Drawings
FIG. 1 is an exemplary illustration of the present invention
FIG. 2 graph of cumulative release (%) of aspirin release curve in example 1
FIG. 3. graph of cumulative release (%) of ticagrelor release profile of example 1
Detailed Description
The invention will be described in further detail with reference to specific embodiments, which are all practical examples and are intended to illustrate the invention in detail, but not to limit the invention.
A compound preparation containing ticagrelor and aspirin.
Example 1
The raw and auxiliary materials are prepared according to the prescription in the table.
Weighing and mixing raw materials and auxiliary materials: weighing aspirin, microcrystalline cellulose and corn starch according to the mass ratio, and uniformly mixing;
and (3) detection: detecting the content of the intermediate particles, and calculating the weight of the pressed tablets;
tabletting: using a single-layer tablet press, adjusting the loading amount and pressure of the tablet press, and controlling the hardness of the total tablet to be 50 +/-20N;
coating: preparing enteric coating solution, and spraying the coating solution when the temperature of the materials reaches 35.0 ℃; controlling the temperature of the material to be 30.0 +/-5.0 ℃, and stopping coating, wherein the weight of the plain tablets is increased to 17.0-20.0% of the weight of the plain tablets; drying in an oven at 60 deg.C for 20h to obtain aspirin enteric-coated tablet.
The raw and auxiliary materials are prepared according to the prescription in the table.
Weighing and premixing raw materials and auxiliary materials: weighing ticagrelor, lactose and anhydrous calcium hydrophosphate according to the mass ratio, and uniformly mixing;
preparation of the adhesive: adding polyvinylpyrrolidone into purified water, and stirring until the solution is clear, transparent and completely dissolved to obtain an adhesive;
and (3) granulating: placing ticagrelor, lactose and anhydrous calcium hydrophosphate in a wet granulation machine, uniformly mixing, adding a binder to prepare a soft material, placing the soft material in a granulating machine after molding, sieving by a sieve of 20 meshes, granulating, drying at 50-60 ℃, controlling the moisture to be less than or equal to 2.00%, and performing dry granulation after the moisture is qualified to obtain a solid composition;
straightening: sieving the dried granules with a 30-mesh sieve for grading;
mixing: adding the granules into the added auxiliary materials according to the proportion respectively, and uniformly mixing;
and (3) detection: detecting the content of the intermediate particles, and calculating the weight of the pressed tablets;
tabletting 1: using a double-layer tablet press, adjusting the loading amount and pressure of the tablet press, and controlling the hardness of the total tablet to be 100 +/-30N to obtain ticagrelor sustained-release tablet plain tablets;
tabletting 2: adding the ticagrelor sustained-release solid composition into a die to perform prepressing for forming by using a tablet press, then adding 1/2 of theoretical tablet weight of the ticagrelor immediate-release solid composition into the die, then placing an aspirin enteric-coated tablet into the middle of the die, and finally adding 1/2 of the ticagrelor immediate-release solid composition into the die to press into a tablet, wherein the total hardness of the tablet is controlled to be 100 +/-30N;
coating: controlling the concentration of the coating liquid to be 15.0% by coating, and starting to spray the coating liquid when the temperature of the material reaches 45.0 ℃; controlling the temperature of the material to be 40.0 +/-5.0 ℃, and stopping coating, wherein the weight of the plain tablets is increased to 2.0-5.0% of the weight of the plain tablets; and drying in a coating pan for 20-30 min to obtain the compound preparation of ticagrelor and aspirin.
The detection result of the in-vitro dissolution curve of the compound preparation of ticagrelor and aspirin is as follows:
fig. 2.
Fig. 3.
From the above results, the novel tabletting method organically combining the core-coated tablet and the double-layer tablet provided by the invention can achieve the effect of releasing the drugs simultaneously and not affecting each other.
The embodiments are not limited by way of example. Other variations and modifications may be made on the basis of the above description. All embodiments need not be exemplified, nor can they be exemplified. Obvious variations or modifications from this index are within the scope of the invention.
Claims (12)
1. The compound preparation of ticagrelor and aspirin, as claimed in claim 1, is characterized in that the tablet core of the compound preparation comprises two parts, namely a quick release core-spun layer and a sustained release layer, wherein the quick release core-spun layer is formed by wrapping an aspirin enteric-coated tablet in the middle of a quick release solid composition of ticagrelor and compressing, and the sustained release layer is formed by compressing a sustained release solid composition of ticagrelor.
2. The sustained release layer of claim 1, wherein the ticagrelor sustained release solid composition comprises one or more of ticagrelor, lactose, mannitol, anhydrous dibasic calcium phosphate, microcrystalline cellulose, hydroxypropyl cellulose, sodium alginate, hydroxyethyl cellulose, methyl cellulose, hydroxypropyl cellulose, polyethylene oxide, carbomer, hydroxypropyl methyl cellulose, polyvinyl pyrrolidone, magnesium stearate, colloidal silicon dioxide.
3. The immediate release core-covering layer according to claim 1, wherein said immediate release solid composition of ticagrelor comprises one or more of ticagrelor, lactose, mannitol, dibasic calcium phosphate anhydrous, corn starch, microcrystalline cellulose, cross-linked polyvinylpyrrolidone, magnesium stearate, sodium carboxymethyl starch, low substituted hydroxypropylcellulose, iron oxide.
4. The immediate release core-covering layer according to claim 1, wherein the aspirin enteric tablet comprises a core component and an enteric coating component. Wherein the tablet core component is composed of one or more of aspirin, microcrystalline cellulose, powdered cellulose, corn starch, and starch slurry, and preferably the filler is microcrystalline cellulose and starch; the enteric coating component is composed of one or more of methacrylic acid, sodium dodecyl sulfate, polysorbate 80 copolymer, pulvis Talci, and triethyl citrate.
5. The sustained release layer according to claims 1-2, wherein the skeleton material is prepared by an external addition method, preferably hydroxypropyl methylcellulose and hydroxypropyl cellulose, most preferably hydroxypropyl methylcellulose K4M, the hydroxypropyl methylcellulose is premixed with a pore-forming agent, the pore-forming agent is selected from one of mannitol, lactose, microcrystalline cellulose and hydroxypropyl methylcellulose E5, and the dosage of the pore-forming agent is 1/5-1/1, preferably 1/2 of hydroxypropyl methylcellulose; hydroxypropyl cellulose can be directly mixed with the additive, and then added with appropriate glidants and lubricants such as colloidal silicon dioxide and magnesium stearate to be mixed and then tabletted.
6. Aspirin enteric-coated tablets according to claims 1 to 4, characterized in that the tabletting manner is selected from one or more of dry granulation, wet granulation and powder direct compression, preferably powder direct compression.
7. A compound ticagrelor and aspirin preparation according to claims 1-6, wherein both ticagrelor and aspirin are sieved, wherein the ticagrelor material is sieved through a 30 mesh sieve, and the aspirin is sieved through a 24-60 mesh sieve.
8. The compound preparation of ticagrelor and aspirin according to claims 1-7, wherein the ticagrelor quick-release raw and auxiliary materials and the ticagrelor sustained-release raw and auxiliary materials are wet-granulated and mixed to obtain a ticagrelor quick-release solid composition and a ticagrelor sustained-release solid composition, and the raw and auxiliary materials of aspirin are mixed, tableted and coated.
9. The process according to claims 1 to 8, wherein the ticagrelor sustained release solid composition is formed by adding the ticagrelor sustained release solid composition to a die and pre-pressing, 1/2 for the theoretical weight of the ticagrelor immediate release solid composition is added to the die, the aspirin enteric coated tablets are placed in the middle of the die, and 1/2 for the theoretical weight of the ticagrelor immediate release solid composition is added to the die and compressed into tablets.
10. The formulation according to claims 1 to 9, characterized in that it is a tablet, comprising in particular: circular tablets, oval tablets, capsule shapes, triangles, quadrilaterals, pentagons, hexagons, etc., with circular and oval tablets being preferred.
11. A compound preparation of ticagrelor and aspirin according to claims 1-10, wherein each unit of the compound preparation contains 60mg, 90mg, 120mg or 180mg, preferably 120mg and 180mg of ticagrelor, and the mass ratio of ticagrelor in the quick-release solid composition to the slow-release solid composition is 5: 1-1: 5, preferably 3: 1-1: 3; each unit contains 75mg or 100mg of aspirin, preferably 100 mg.
12. The compound preparation of ticagrelor and aspirin according to claims 1-11, wherein the tablet core of the compound preparation is coated with a color coat, preferably a moisture-proof coating powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010926574.7A CN111939136A (en) | 2020-09-07 | 2020-09-07 | Compound preparation containing ticagrelor and aspirin and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010926574.7A CN111939136A (en) | 2020-09-07 | 2020-09-07 | Compound preparation containing ticagrelor and aspirin and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111939136A true CN111939136A (en) | 2020-11-17 |
Family
ID=73356243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010926574.7A Pending CN111939136A (en) | 2020-09-07 | 2020-09-07 | Compound preparation containing ticagrelor and aspirin and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111939136A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114533694A (en) * | 2020-11-26 | 2022-05-27 | 乐普（北京）医疗器械股份有限公司 | Compound capsule preparation containing ticagrelor and aspirin and preparation method thereof |
| CN114533744A (en) * | 2020-11-26 | 2022-05-27 | 乐普（北京）医疗器械股份有限公司 | Ticagrelor-aspirin compound pellet preparation and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014191321A1 (en) * | 2013-05-29 | 2014-12-04 | Ratiopharm Gmbh | Solid pharmaceutical dosage form |
| CN104434931A (en) * | 2014-11-06 | 2015-03-25 | 南京华威医药科技开发有限公司 | Compound oral solid preparation containing ticagrelor and aspirin and preparation method of solid preparation |
| CN106619549A (en) * | 2017-01-03 | 2017-05-10 | 江苏吴中医药集团有限公司苏州制药厂 | Ticagrelor and aspirin compound tablet and preparation method thereof |
| CN107260700A (en) * | 2016-04-09 | 2017-10-20 | 厦门恩成制药有限公司 | A kind of preparation method of ticagrelor compound oral solid pharmaceutical preparation |
| CN109806261A (en) * | 2019-03-11 | 2019-05-28 | 梁江丽 | A kind of ticagrelor sustained release preparation and its preparation and application |
-
2020
- 2020-09-07 CN CN202010926574.7A patent/CN111939136A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014191321A1 (en) * | 2013-05-29 | 2014-12-04 | Ratiopharm Gmbh | Solid pharmaceutical dosage form |
| CN105377240A (en) * | 2013-05-29 | 2016-03-02 | 拉蒂奥法姆有限责任公司 | Solid pharmaceutical dosage form |
| CN104434931A (en) * | 2014-11-06 | 2015-03-25 | 南京华威医药科技开发有限公司 | Compound oral solid preparation containing ticagrelor and aspirin and preparation method of solid preparation |
| CN107260700A (en) * | 2016-04-09 | 2017-10-20 | 厦门恩成制药有限公司 | A kind of preparation method of ticagrelor compound oral solid pharmaceutical preparation |
| CN106619549A (en) * | 2017-01-03 | 2017-05-10 | 江苏吴中医药集团有限公司苏州制药厂 | Ticagrelor and aspirin compound tablet and preparation method thereof |
| CN109806261A (en) * | 2019-03-11 | 2019-05-28 | 梁江丽 | A kind of ticagrelor sustained release preparation and its preparation and application |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114533694A (en) * | 2020-11-26 | 2022-05-27 | 乐普（北京）医疗器械股份有限公司 | Compound capsule preparation containing ticagrelor and aspirin and preparation method thereof |
| CN114533744A (en) * | 2020-11-26 | 2022-05-27 | 乐普（北京）医疗器械股份有限公司 | Ticagrelor-aspirin compound pellet preparation and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6122098B2 (en) | Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or a salt thereof | |
| KR100780553B1 (en) | Pharmaceutical compositions and formulations of Metformin extended release tablets and its preparing method | |
| CN101703513B (en) | Compound sustained-release preparation of aspirin and clopidogrel or pharmaceutically acceptable salt thereof | |
| WO2008062273A2 (en) | Solid oral dosage form having antidiabetic drug combination | |
| CN103070864B (en) | Repaglinide and metformin hydrochloride medicinal composition and its preparation method | |
| CN111939136A (en) | Compound preparation containing ticagrelor and aspirin and preparation method thereof | |
| CN103006649A (en) | Compound preparation of valsartan amlodipine tablet (I) and preparation method thereof | |
| CN109875972B (en) | Olmesartan medoxomil and amlodipine pharmaceutical composition | |
| CN101843615A (en) | Dispersible tablets containing valsartan and amlodipine besylate and preparation method thereof | |
| CN103655505B (en) | A kind of pain relieving class two-layer release-controlled tablet and preparation method thereof | |
| WO2015154656A1 (en) | Controlled-release solid preparation with partial coating | |
| CN101836963B (en) | Medicinal application preparation for curing hypertension | |
| CN111991362A (en) | Ticagrelor sustained release tablet and preparation method thereof | |
| CN102247366B (en) | Medicinal compositionslow-releaseformulation containing Enalapril and Felodipine | |
| CN101756916A (en) | Compound vitamin B6 sustained release tablets and preparation process thereof | |
| CN103690503B (en) | A kind of preparation method of double-layer tablet | |
| CN101524355A (en) | Compound preparation of antituberculosis medicaments, and preparation method thereof | |
| CN100577152C (en) | Losartan potassium and hydrochlorothiazide tablets and preparation method thereof | |
| CN103690505A (en) | Hypnotic double-layer controlled release tablet and preparation method thereof | |
| CN114533694A (en) | Compound capsule preparation containing ticagrelor and aspirin and preparation method thereof | |
| CN103860511A (en) | Pharmaceutical composition containing irbesartan and amlodipine benzenesulfonate and preparation method thereof | |
| CN101474163A (en) | Lovastatin and niacin sustained-release preparation and preparation method thereof | |
| CN114533744A (en) | Ticagrelor-aspirin compound pellet preparation and preparation method thereof | |
| CN101732269A (en) | Dispersible tablets containing isosorbide mononitrate | |
| CN101623282B (en) | Aspirin-dipyridomole sustained-release capsule and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20201117 |
|
| WD01 | Invention patent application deemed withdrawn after publication |